【摘要】 目的 对比分析新生血管性年龄相关性黄斑变性(nAMD)患者使用法瑞西单抗或雷珠单抗治疗前后的变化。方法 前瞻性研究，纳入华东师范大学附属芜湖医院眼科就诊的nAMD患者20例(20眼),经荧光素眼底血管造影和(或)吲哚菁绿血管造影及OCT确诊的nAMD患者，使用SS-OCTA测量患者在抗VEGF基线和治疗4周、12周和24周时的黄斑中心凹视网膜厚度(CMT)、CNV截面面积(CSA)、CNV血流面积(CFA),对比患者在各时间段指标的变化以及两组间的差异。结果 两组患者基线时的年龄、性别、CNV类型、OCT及OCTA形态之间差异均无统计学意义(均为P>0.05)。两组患者的CMT、CSA、CFA均在治疗后降低(均为P<0.05),CMT变化显示，两组患者在治疗4周、12周时逐渐递减(均为P<0.05),在24周时法瑞西单抗组患者CMT与12周时相比差异无统计学意义(P=0.096),雷珠单抗组患者CMT相比12周时增加(P=0.004);CSA、CFA变化显示两组患者均在治疗后12周减小(均为P<0.05),在24周时法瑞西单抗组患者CSA、CFA与12周时相比差异无统计学意义(P=0.085、0.095),雷珠单抗组患者CSA、CFA相比12周时增大(P=0.001、0.000)。组间对比结果显示，法瑞西单抗组患者的CMT在治疗24周时低于雷珠单抗组患者(P=0.022),CSA、CFA在各时间点两组患者间相比差异均无统计学意义(均为P>0.05)。结论 法瑞西单抗与雷珠单抗在nAMD患者的疗效上相近，而在疗效的持续性方面法瑞西单抗优于雷珠单抗。更多还原

【Abstract】 Objective To analyze the changes in patients with neovascular age-related macular degeneration(nAMD) before and after treatment with faricimab or ranibizumab. Methods A prospective study was conducted on 20 nAMD patients(20 eyes) who received treatment at the Ophthalmology Department of Wuhu Hospital affiliated with East China Normal University. nAMD was diagnosed with fluorescein fundus angiography, indocyanine green angiography, and optical coherence tomography(OCT). The central macular thickness(CMT), choroidal neovascularization(CNV) cross-sectional area(CSA), and CNV blood flow area(CFA) of the patients at baseline and after 4, 12, and 24 weeks of anti-vascular endothelial growth factor(VEGF) treatment. The changes in index at different time periods and the differences in results between the two groups were studied. Results There were no statistically significant differences in age, gender, CNV type, OCT, and optical coherence tomography angiography(OCTA) morphology between the two groups of patients at baseline(all P>0.05). CMT, CSA, and CFA decreased in both groups after treatment(all P<0.05). CMT showed a gradual decrease in both groups after 4 and 12 weeks of treatment(all P<0.05). There was no statistically significant difference in CMT between 12 and 24 weeks after treatment in the faricimab group(P=0.096). In the ranibizumab group, CMT increased 24 weeks after treatment, compared with that 12 weeks after treatment(P=0.004). CSA and CFA decreased in both groups after 12 weeks of treatment(both P<0.05). There was no statistically significant difference in CSA and CFA between 12 and 24 weeks after treatment in the faricimab group(P=0.085, 0.095). In the ranibizumab group, CSA and CFA increased 24 weeks after treatment, compared with those 12 week after treatment(P=0.001, 0.000). Inter-group comparisons showed that the CMT of patients in the faricimab group was lower than that in the ranibizumab group after 24 weeks of treatment(P=0.022). There was no statistically significant difference in CSA and CFA at each time period for both groups(all P>0.05). Conclusion Faricimab and ranibizumab have similar efficacy in the treatment of nAMD patients, but faricimab is superior to ranibizumab in sustained effects.更多还原